Could CAR-T cell therapy improve kidney transplants?

Mayo Clinic researchers have found that chimeric antigen receptor-T cell therapy (CAR-T cell therapy) could be a groundbreaking approach for organ transplantation, particularly for patients who are hard to match and at risk of rejection. The research focuses on using CAR-T cells derived from the patient’s own immune system to prevent rejection of donated organs, specifically targeting B cells that cause sensitization in patients awaiting kidney transplants. This study demonstrates the potential of CAR-T cell therapy in desensitizing kidney transplant patients and reducing the wait time for organ transplants. Further research is needed to validate these findings and explore the use of CAR-T cell therapy beyond cancer treatment.

Source link

error: Content is protected !!